Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV-infected people on opioid agonist therapy.

Journal of viral hepatitis - 1 Jun 2021

Macías Juan, Téllez Francisco, de Los Santos Ignacio, Morano Luis E, Merino Dolores, Granados Rafael, Vera-Mendez Francisco, González-Serna Alejandro, Campo-Moneo Esther, García-Fraile Lucio, García Federico, Real Luis M, Pineda Juan A

Abstract excerpt

Elbasvir/grazoprevir (EBR/GZR) use in drug users on opiate agonist therapy (OAT) is supported by the C-EDGE Co-STAR trial. SVR rates in this study were within those found in the rest of patients included by the EBR/GZR development programme. In clinical practice, however, efficacy could theoretically be lower. Thus, we aimed at evaluating the SVR rates of EBR/GZR among people who injected drugs (PWID) with and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amides
Share to Analgesics, Opioid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzofurans

Share to Carbamates

Share to Cyclopropanes

Share to Imidazoles

Share to Pharmaceutical Preparations

Share to Quinoxalines

Source

Identifiers

PMID: 33721377
DOI: 10.1111/jvh.13496

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV-infected people on opioid agonist therapy.PMID 33721377Read ↗

Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.Semantic proximity Read ↗

Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population.Semantic proximity Read ↗

Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.Semantic proximity Read ↗

Elbasvir/grazoprevir for the treatment of hepatitis C virus infection in people with opioid use disorder.Semantic proximity Read ↗

Epidemiology of hepatitis C virus infection among people receiving opioid substitution therapy (ECHO): study protocol.Semantic proximity Read ↗

Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.Semantic proximity Read ↗

Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.Semantic proximity Read ↗

Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study.Semantic proximity Read ↗

Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy : Final results of the Austrian PegHope study.Semantic proximity Read ↗

High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use.Semantic proximity Read ↗

Management of hepatitis C virus (HCV) infection in drug substitution programs.Semantic proximity Read ↗

Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.